echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > What will 100 Chinese new drug development leaders talk about behind closed doors?

    What will 100 Chinese new drug development leaders talk about behind closed doors?

    • Last Update: 2020-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Guide: With the collision of these leaders' ideas, we have been able to discover effective reference samples for the development of new drugs in China and see the opportunities for change in the next decade.
    notable phenomenon is that with the reform and promotion of the State Drug Administration, the "highway" of innovative drugs in China is widening.
    with the participants of the New Drug Research and Development Leaders Summit in July this year, the new version of the "Drug Registration Management Measures" officially implemented, opening a new wave of industrial change.
    just a few days ago, in line with the Measures for the Administration of Drug Registration, the State Drug Administration has issued three working procedures, respectively, involving the review of breakthrough therapeutic drugs, conditional approval, priority review and approval, etc., and will undoubtedly further activate the innovative elements of all parties.
    , however, the industry still has to face such doubts: "highway" has, can go on the road "car" where? Take double resistance as an example, public information shows that the world in the preclinical stage of antibody drugs, about 20% of the double resistance, and domestic double-resistance projects mainly concentrated in phase II, overall to fast follow-based.
    to the target selection of antibody drugs, PD-1 has undoubtedly become the focus of many pharmaceutical companies, the domestic track is becoming more crowded, the imagination of the latter is shrinking.
    to 2020, from the original project to the transformation of differentiated development, has become more and more domestic pharmaceutical companies consensus.
    and under the pressure of policies such as "belt procurement", it is more urgent to think about how to get out of their own path of original new drugs. On July 9,
    , jinji lake China's new drug research and development leaders summit in Suzhou as scheduled.
    as the prelude to the 2nd Global Conference on Frontier Sede Technologies and Policy and Regulation in BioBAY, which was jointly organized by BioBAY and the New Medicine Stakes Club, brought together more than 100 domestic pharmaceutical industry leaders.
    among them, there are no shortage of new drug research and development pioneers and practitioners, and even have made remarkable achievements.
    through the collision of these leaders' ideas, we have been able to discover effective reference samples for the development of new drugs in China and see the opportunities for change in the next decade.
    's leadership speech Suzhou Industrial Park Party Work Committee member, deputy director of the Management Committee in Suzhou every year, writing will give us a series of exciting activities.
    this year's "New Crown" outbreak of global epidemic, Suzhou to build the city's efforts to build a global biopharmaceutical industry landmark background, Dr. Cheng Zengjiang and Mayor Li Yaping organized this Jinji Lake China's new drug research and development leaders closed-door meeting, with a very special significance, will certainly add new impetus and vitality to the development of suzhou biopharmaceutical industry.
    the biopharmaceutical industry continues to develop, and then climb the peak, we need to work together.
    we hope to use the east wind of this conference, and entrepreneurs, experts and scholars in the field of biomedicine, to continue friendship, joint business development, and share success.
    China's First In Class New Drug Path"? Dare to do it? Will it be done? "This is a series of "soul tortures" about China's first in class new drug path, so that the seminar quickly entered into a warm atmosphere.
    and its founder, Zhai Shi, have provided nutrients and air for the birth of the local first in class, as a large number of overseas talents and technical resources have poured into China, coupled with the continued growth of China's economy and the release of the dividends of pharmaceutical innovation policies.
    participants agreed that China's first in class new drugs can do, dare to do, will do, to dare to "break the problem", the courage to self-breakthrough, local new drug research and development enterprises also have such wisdom, but must be highly confident.
    Where is the path of the first in class new drug as the panel discussion continues? How to answer the question, how to solve the problem, the guests hold their views.
    point of view: the new target, the new treatment is the direction of the first in class new drug, can create more value for society, for patients to solve the disease problem earlier.
    Point 2: It is not necessary to tangle the nature of first in class, from the perspective of solving medical needs for patients, in fact, the new characteristics of the existing target drug, the discovery of new indications, can provide a unique opportunity for the solution of the problem of patients in China, and more quickly and effectively.
    no matter how the first in class research and development path is chosen, but in the essence of cognitive research and development, there is a consensus: the essence of the drug is to cure and save people, there is no clinical value is the fundamental of drug innovation, otherwise will not be able to survive space.
    new drug development must make a breakthrough in clinical value.
    is so-called, whether it is a white cat black cat, caught a mouse is a good cat;
    in the new drug research and development of the way to the nuggets, known as the "selling shovel" CRO company, is also an indispensable force in the development of new drugs.
    outsourcing clinical services not only helps pharmaceutical companies to shorten the time to market and save costs, but also has become an important way to develop new drugs. How
    will lay out the next decade of China's new drugs? As we all know, the cost and time of successfully developing a new drug is increasing, and in the eyes of many people, innovation seems to be becoming the "game" of a few pharmaceutical companies.
    this is largely because known targets are being consumed, and the exploration of unknown mechanisms is difficult, and progress in basic research is still some time far from being made.
    In addition to looking at the path of first in class, some pharmaceutical companies are also trying to break through existing conditions.
    , for example, with the use of currently known targets, step by step to optimize the way the drug works, so as to make a better product than the former - the development of tinib drugs, that is, the practice of such a mainstream path.
    because kinase inhibitors compete with ATP and bind to proteins for a long time, mainly by inhibiting kinase activity.
    this kind of exposure for a long time, it is easy to induce tumor cells to produce corresponding drug-resistant mutations.
    the industry is developing a new generation of drugs in response to emerging factors. Li Jing, founder of
    Pharmaceutical Ferry, reminded the participants that the next 10 to 20 years of international innovation may show a double-function or multi-functional drug boom.
    in other words, even the current "old medicine" on the market, or the results of the research and maturity, is expected to be secondary development through pathways such as combination therapy, and ultimately promote the emergence of innovative drugs.
    on the other hand, the influence factors of the longer cycle of the drug, including the cognitive misunderstanding of drug research and development.
    pharmaceutical policies, capital-boosting and brain-returning, these changes have led to the emergence of a number of biotech start-ups in China in recent years.
    However, these high-profile innovators are actually having a hard time pushing a new drug to the market.
    , cooperation will therefore be a benign normal for the development of new drugs in China.
    small companies have the strength of the vitality of innovation, can quickly try potential ideas, get the initial results.
    and large pharmaceutical companies have the scale and cost advantage, can verify the initial results, so that it continues to improve and speed up the listing declaration.
    cooperation between the two sides, not only make the start-up's innovative ideas to continue, get more funds to support scientific research, but also conducive to large companies' high-quality pipeline expansion and enrichment, but also to create social benefits to meet the clinical needs of patients.
    noteworthy, some experts believe that Compared with the drug development a decade ago, China has not really achieved a breakthrough in the mebetter drug, at best, in the me too. Why
    ? The crux behind this is that the larger environment of the past is not clinically demand-oriented drug development.
    now, first in class is good, innovative drugs are also, in the final analysis, is still to achieve clinical needs of the best in class.
    focus on this point, you can see that Chinese patients, PI and even make a very big contribution.
    the same guidelines, cases in China are relatively concentrated.
    some new drugs are being clinically advanced, efficiency, speed and international comparison may be even faster.
    the level of New Drugs in China to take it to the next level, its research and development should be international-oriented.
    In addition to the internationalization of clinical trial design, more innovative drugs also depend on the support of international markets.
    in view of the differences in payment system, the current Chinese market is difficult to achieve the return of new drug innovation, the European and American markets have become one of the important directions that innovators need to pay attention to.
    Shenzhen Yino Micro Pharmaceutical Technology Co., Ltd. founder and CEO Zhou Guoxuan finally, how to layout China's new drugs? This may not be a general matter, but rather the in-depth consideration of individual companies in their own situation.
    participants said that if enterprises have the ability to develop Chinese medicine, the current environment should be a good opportunity for the development of Chinese medicine, but this does not mean that not to take the road of Chinese medicine.
    from the product point of view, Chinese medicine, chemical drugs, biological drugs, the next decade may be more opportunities for biological drugs, the possibility of success is greater.
    Dinner Part Of the Guest List 1 Dr. He Ruyi: Chairman of the New Drug Talent Club, former CDE Chief Scientist 2 Zhu Xun Dr.: 3 Pang Junyong: Chairman and President of Suzhou Industrial Park Biodevelopment Industry Development Co., Ltd. 4 Cheng Zengjiang: Cobeiyuan (Beijing) Biopharmaceutical Technology Co., Ltd. Chairman, Co-Writing Forum Founder 5 Dr. Yang Qing: Dr. Kant Co-CEO 6 Xiao Ruiping: And its Co-Founder, Chairman and CEO Dr. 7 Sun Yongkui: National Academy of Engineering, Chairman of The Raw Life Sciences, Director of the New Drug Talent Club 9 Dr. Chen Zhisheng: Dr. 10 Zhou Guoxuan, CEO of Pharmaceutical Ming Bio: Founder of Shenzhen Yino Micropharmaceutical Technology Co., Ltd., CEO 11 Dr. Li Jin: Founder of Chengdu Pilot Pharmaceutical Development Co., Ltd., Chairman and CEO 12 Lihua: Cytiva Greater China General Manager 13 Dr. Yuan Jiandong: Chairman and President of Berry Biopharmaceuticals (Suzhou) Co., Ltd. 14 Li Jianfeng: Dr. 15 Xu Wei, General Manager of Pharmaceutical and Biotechnology and Nutrition Business, Longsha Group China, Switzerland: Corning Jerry Founder, Chairman, CEO 17 Sheng Zelin: Suzhou Zeyu BioPharmaceutical Co., Ltd., Founder, Chairman, Chairman and Chairman, Dr. : Dr. 20 Qian Xueming, Managing Director of Merck China Innovation Center and Vice President of Strategy and Transformation in China: Co-founder and CEO of The Same-Writing Antibody Talent Club, Dr. 21 Lu Hongxuan: Co-founder and Chief Scientific Officer of Kwun Pharmaceuticals, Dr. 22 Tian Wenzhi: Dr. 23 Bi Honggang, Chairman and General Manager of Yiming Angke: Dr. Covins Global Senior Vice President, Asia Pacific Head, China General Manager Dr. Dr. 25 Fu Daotian, Founder and CEO of Shore-Mai Bio: Dr. Fu Daotian, Director of the Same-Writing Antibodies Talent Club, President of Rongchang Biopharmaceuticals 26 Fan Xiaohu: Co-Founder of Nanjing Legendary Biotech Co., Ltd., CSO27 Wang Liqun: Fosun Kate Biotech Co., Ltd. President 28 Dr. Zhang Yu: Vice General Manager of Zhongyuan Concord Cell Genetic Engineering Co., Ltd., Chief Scientific Officer 29 Dr. Liu Chuan: Chairman and Chief Scientific Officer of Colin Likang Medical Research Co., Ltd., Beijing, Dr. 31 Ke Huazhu, Chairman of En PharmaceuticalS: Founder and CEO of Anjisheng Biopharmaceutical Technology (Guangzhou) Co., Ltd., Dr. 32 Wen Shuhao: Co-founder and chairman of Shenzhen Jingtai Technology Co., Ltd., Chairman 33 Xie Yuli: Microbiopheric Bio/Even-Collar Biology Founder, General Manager 34 Dr. Zhang Jianxuan: Dr. 35 Qianfeng, Chairman of Hengnokang Pharmaceutical Technology Co., Ltd., Guangzhou: Vice President of Tsinghua University Pharmaceutical Academy, Dr. 36 Wang Qingsong, Founder of Yapan Biotech, Dr. 37 Song Yan, Founder and CEO of Nanjing Qingpu Bio: Founder and CEO of Guangzhou Lead Medical Technology Co., Ltd.: Dr. 39 Zhaolong, Managing Director of Junlian Capital: Dr. 40 Chen Weihui, Chairman and CEO of Yidi Pharmaceuticals: Dr. 41 Ye Weiping, General Manager of Guangdong Zhongyi Pharmaceutical Co., Ltd.: 42 Weeks Xinhua, CEO, Guangdong Raffles Pharmaceutical Technology Co., Ltd.: Dr. Dr. Charlie: Director of southern University of Science and Technology - Hengpu Life Sciences Research Center, founder and chairman of Hopkins Medical Research Institute Co., Ltd., 44 Huawei: Dr. Yuhui Pharmaceutical Technology Co., Ltd., CEO 45 Wang Yuqi: Dr. Yingshi Biological Chairman and CEO 46 Chen Xiaoxin: Director, Co-Founder, President 47 Li Jing: Dr. 48 Dr. Liu Jing: Cytiva Great China Chief Scientist, Technical Application Director Dr. 49 Chen Chunlin: Shanghai Medi-Si Biopharmaceutical Co., Ltd. Founder and CEO 50 Panke Dr. : Yahong Pharmaceutical Co-Founder, Chairman and CEO Dr. 51 Jing Shuqian: Hongyun Huaning (Hangzhou) Biopharmaceutical Co., Ltd. Founder, Chairman and CEO Dr. 52 Luoshun: Founder and President of Jianshun Biotech Co., Ltd., Founder and President of Auscom Biopharmaceuticals (Haimen) Co., Ltd. 3 Dr. Ma Zhenkun: Dr. 54 Pan Hai, Founder and CEO of Danno Pharmaceuticals: Dr. 55 Tongyou, Founder and CEO of Da Biotech Co., Ltd.: Dr. 560,000 Zhaokui, Founder and CEO of Pioneering Pharmaceuticals: Dr. 57 Wang Yaolin, Chairman and General Manager of Lingke Pharmaceuticals: Dr. 58 Yu Qiang, Co., Co., Ltd., Yifang Biopharmaceuticals, Founder, Chairman and CEO, Sheng Shitaike Technology (Suzhou) Co., Ltd., DR. 59 ZHANG INVENTION: DR. HUASHITONG BIOPHARMACEUTICAL CO., LTD. CEO 60 ZHU YI: CHAIRMAN OF BAILI PHARMACEUTICAL CO-FOUNDER, DIRECTOR AND CHIEF OPERATING OFFICER OF RUI PHARMACEUTICAL CO-FOUNDER, DIRECTOR AND CHIEF OPERATING OFFICER 62 ZHANG JINTAO DR.: JES INDA FOUNDER, CEO 63 QI XUEBING: CHAIRMAN AND PRESIDENT OF BEIJING HAIJINGE PHARMACEUTICAL TECHNOLOGY CO., LTD. 64 CHEN YONG Dr. Qing: Guoxin Pharmaceutical Technology (Beijing) Co., Ltd. Chairman 65 Xuan Zhenyu Dr.: Suzhou Yusen New Drug Development Co., Ltd. founder, Chairman 66 InBev Dr.: Suzhou Aibo Biotech Co., Ltd. Founder 67 Qin Jianfei: Harbin Sanlian Pharmaceutical Co., Ltd. Chairman and General Manager 68 Chuhong Dr. : Suzhou Teri Pharmaceutical Co., Ltd. Chairman Of the General Manager 69.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.